ICAPS

ICAPS

• The International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS) was developed to facilitate the discovery of new genetic variants that are important for predicting response to antihypertensive drugs using genome wide association studies (GWAS) and other methods.
• ICAPS includes 29 cohorts with > 345,000 participants from 22 different research groups based in 10 countries on 3 continents.
• Available phenotypes include blood pressure response, adverse metabolic response (including hypokalemia, hyponatremia, hyperglycemia, hyperuricemia and others), long-term cardiovascular outcomes (including heart attack, stroke and death), and long-term risk for diabetes.

The goal of ICAPS is to advance pharmacogenomics discoveries for antihypertensive drugs that will lead to definitive evidence regarding use of genetic information to guide anti-HTN treatment decisions.